The venous thromboembolism is one of the first causes of maternal mortality. Until 2003, only a few recommendations were available on the optimal use of antithrombotic therapy as a preventive measure against thromboembolism in pregnant women. In this study, we propose :
- To gather the experts who took part in the French consensus conference and the local experts to create a score in accordance with the national and international consensus and to give some precise therapeutic strategies.
- To evaluate the discriminant, feasible and useful character of this new score by a random prospective multicentric study including 2280 pregnant women with a risk of thromboembolism or placental vascular pathology who will benefit from therapeutic strategies defined by the new score.
Primary Outcome Measures:
- Occuring of symptomatic thromboembolic events, and/or placental vascular pathology, and/or any other pregnancy pathology requiring hospitalization and/or any complications from the antithrombotic treatment [ Time Frame: first, second or third trimester during pregnancy or post-partum ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||December 2012 (Final data collection date for primary outcome measure)
Purpose : To create a score inspired by our first experience i.e. simple, standardized and quickly usable in day-to-day practice to individualize antithrombotics prescription to women at risk.